Propranolol for Anxiety in Children: Not Recommended as Standard Treatment
Propranolol is not recommended as a standard treatment for anxiety disorders in children. The most authoritative guideline on pediatric anxiety disorders does not include propranolol among evidence-based treatments, instead recommending cognitive-behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) as first-line interventions 1.
Evidence Base
Guideline Recommendations
The 2020 American Academy of Child and Adolescent Psychiatry clinical practice guideline for anxiety disorders in children and adolescents makes no mention of propranolol as a treatment option 1. This guideline identifies:
- First-line treatments: CBT and SSRIs with substantial empirical support
- Second-line: SNRIs with some empirical support
- No recommendation for beta-blockers in pediatric anxiety disorders
Research Evidence Shows Limited Efficacy
The available research evidence is weak and contradictory:
A 2025 systematic review and meta-analysis of beta-blockers for anxiety disorders found no evidence of beneficial effect compared to placebo or benzodiazepines in social phobia or panic disorder (p ≥ 0.54 for all analyses) 2
A 2024 randomized controlled trial in autism spectrum disorder (n=74) found no significant effect on social interaction or language, with only marginal benefit for anxiety at 12 weeks (p=0.045, OR=2.58) 3
A 1993 review concluded evidence was "weak" for treating anxiety disorders with propranolol in children, noting most trials were small, uncontrolled, and used suboptimal doses 4
Limited Positive Findings
The only context where propranolol showed some benefit was:
- One open trial for post-traumatic stress disorder showing response in anxiety and aggression 4
- Anecdotal reports for performance anxiety/school refusal with somatic symptoms 5
- These findings are from small, uncontrolled studies and cannot support routine use
FDA Labeling Position
The FDA label explicitly states: "Safety and effectiveness of propranolol in pediatric patients have not been established" 6. The label further warns that bronchospasm and congestive heart failure have been reported in pediatric patients receiving propranolol 6.
Dosing Information (When Used Off-Label)
While not recommended for anxiety, when propranolol is used off-label in children for other conditions (e.g., infantile hemangiomas), the dosing framework is:
For infantile hemangiomas (the only well-established pediatric use):
- Starting dose: 1 mg/kg/day divided into 2-3 doses 7
- Maintenance dose: 2 mg/kg/day divided 7
- Maximum: 3 mg/kg/day 7
For challenging behaviors in autism (retrospective case series only):
- Doses ranged 120-960 mg/day (mean 462 mg/day) as add-on therapy 8
- This represents high-dose use requiring close cardiovascular monitoring
Critical Safety Considerations
If propranolol were to be considered off-label for anxiety (which is not recommended):
Absolute contraindications:
- Hypoglycemic episodes (recent or ongoing)
- Second or third-degree heart block
- Hypersensitivity to propranolol 7
Pre-treatment requirements:
- Cardiovascular and respiratory examination (auscultation, peripheral pulses)
- ECG if: HR outside normal range, family history of sudden death/arrhythmia, syncope episodes
- Baseline glucose only if: preterm, low weight, faltering growth, feeding difficulties 7
Monitoring concerns:
- Risk of hypoglycemia, especially with reduced feeding
- Bradycardia and hypotension
- Bronchospasm risk
- Must ensure regular feeding to prevent hypoglycemia 7
Clinical Bottom Line
Use evidence-based treatments for pediatric anxiety: CBT as first-line, SSRIs if needed, and SNRIs as additional options 1. Propranolol lacks both guideline support and robust efficacy data for anxiety in children. The 2025 meta-analysis definitively shows no benefit over placebo 2, and the FDA has not established safety or effectiveness in pediatric populations 6.
The increasing off-label prescribing of beta-blockers for anxiety (documented between 2003-2018) is occurring without adequate evidence base 2. This practice should be discouraged until definitive RCT data demonstrate benefit.
Common pitfall: Confusing propranolol's use for performance anxiety in adults (situational, somatic symptoms) with treatment of pediatric anxiety disorders—these are distinct clinical scenarios with different evidence bases.